Laimimer Kuilan-Torres
FDA investigator
Appears on 1 document from 2022, mostly at sites in China. Most often cites production record review (21 CFR 211.192).
- 1
- Documents on file
- 3.0
- Observations per 483
- 2022
- First seen
- 2022
- Most recent
What they cite most
From 3 observations- 21 CFR 211.192Production record review1
- 21 CFR 211.67Equipment cleaning and maintenance1
Activity by year
2022: 1
Where
China 1
Often inspects with
Is Laimimer Kuilan-Torres coming to your site?
Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.
Ask about any investigator in Claude or ChatGPT with the AI connector.
Inspection history
1 document, newest first| Date | Firm | Location | Observations | Open |
|---|---|---|---|---|
| 2022-03-04 | 483 Zhejiang Tianyu Pharmaceutical Co. LtdMar 4, 2022 · Taizhou City, China | Taizhou City, China | 3 |
About this profile
What does Laimimer Kuilan-Torres inspect?
Laimimer Kuilan-Torres appears on 1 document on file covering 1 site, mostly in China.
What do they cite most often?
21 CFR 211.192 (production record review), followed by 21 CFR 211.67.
Can I read the observations?
Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.
How current is this profile?
The most recent document on file for Laimimer Kuilan-Torres is dated Mar 4, 2022.